MicroRNA‑296‑5p inhibits cell proliferation by targeting HMGA1 in colorectal cancer

Yan,Guohui; Yan,Shuidi; Wang,Jiajia; Lei,Shen; Tian,Weimin; Yue,Xin; Zhang,Yang

doi:10.3892/etm.2021.10225

MicroRNA‑296‑5p inhibits cell proliferation by targeting HMGA1 in colorectal cancer

Authors:
- Guohui Yan
- Shuidi Yan
- Jiajia Wang
- Shen Lei
- Weimin Tian
- Xin Yue
- Yang Zhang
View Affiliations

Affiliations: The Medical Department of the Xiamen University, Xiamen, Fujian 361000, P.R. China, Center of Clinical Laboratory, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, Fujian 361004, P.R. China, The Medical Department of the Fujian Medical University, Fuzhou, Fujian 350000, P.R. China, Department of Paediatrics, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Imaging, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, Fujian 361004, P.R. China
Published online on: May 24, 2021 https://doi.org/10.3892/etm.2021.10225
Article Number: 793

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing body of evidence indicates the involvement of microRNAs (miRNAs/miRs) in the initiation and progression of colorectal cancer (CRC). miR‑296‑5p was recently identified as a tumor suppressor in a variety of human cancer types; however, its function in CRC remains largely unknown. The present study demonstrated that the expression of miR‑296‑5p was significantly downregulated in CRC tissues and cell lines. The overexpression of miR‑296‑5p markedly inhibited proliferation, and induced cell cycle arrest and apoptosis in CRC cells. Bioinformatics analysis suggested that high mobility group AT‑hook 1 (HMGA1) may be a target of miR‑296‑5p in CRC cells. Further experiments showed that miR‑296‑5p bound the 3'‑untranslated region of HMGA1 and decreased its expression in CRC cells. HMGA1 was overexpressed in CRC tissues and was inversely correlated with the expression of miR‑296‑5p. The restoration of HMGA1 significantly reversed the inhibitory effect of miR‑296‑5p on the proliferation of CRC cells. Overall, the findings of the present study indicate that miR‑296‑5p suppressed the progression of CRC, at least partially via targeting HMGA1. Thus, miR‑296‑5p is a potential target for novel therapies in CRC.

View Figures

View References

1	Sabit H, Cevik E and Tombuloglu H: Colorectal cancer: The epigenetic role of microbiome. World J Clin Cases. 7:3683–3697. 2019.PubMed/NCBI View Article : Google Scholar
2	Fakih MG: Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 33:1809–1824. 2015.PubMed/NCBI View Article : Google Scholar
3	Simon K: Colorectal cancer development and advances in screening. Clin Interv Aging. 11:967–976. 2016.PubMed/NCBI View Article : Google Scholar
4	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004.PubMed/NCBI View Article : Google Scholar
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
6	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
7	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 79:351–379. 2010.PubMed/NCBI View Article : Google Scholar
8	Valenti MT, Dalle Carbonare L and Mottes M: Role of microRNAs in progenitor cell commitment and osteogenic differentiation in health and disease (Review). Int J Mol Med. 41:2441–2449. 2018.PubMed/NCBI View Article : Google Scholar
9	Gentilin E, Degli Uberti E and Zatelli MC: Strategies to use microRNAs as therapeutic targets. Best Pract Res Clin Endocrinol Metab. 30:629–639. 2016.PubMed/NCBI View Article : Google Scholar
10	Momtazi AA, Shahabipour F, Khatibi S, Johnston TP, Pirro M and Sahebkar A: Curcumin as a microRNA regulator in cancer: A review. Rev Physiol Biochem Pharmacol. 171:1–38. 2016.PubMed/NCBI View Article : Google Scholar
11	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 9(852)2017.PubMed/NCBI View Article : Google Scholar
12	Asadzadeh Z, Mansoori B, Mohammadi A, Aghajani M, Haji-Asgarzadeh K, Safarzadeh E, Mokhtarzadeh A, Duijf PHG and Baradaran B: microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities. J Cell Physiol. 234:10002–10017. 2019.PubMed/NCBI View Article : Google Scholar
13	Kwak PB, Iwasaki S and Tomari Y: The microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.PubMed/NCBI View Article : Google Scholar
14	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.PubMed/NCBI View Article : Google Scholar
15	Qu H, Xu W, Huang Y and Yang S: Circulating miRNAs: Promising biomarkers of human cancer. Asian Pac J Cancer Prev. 12:1117–1125. 2011.PubMed/NCBI
16	Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 233:5574–5588. 2018.PubMed/NCBI View Article : Google Scholar
17	Wang B, Lu FY, Shi RH, Feng YD, Zhao XD, Lu ZP, Xiao L, Zhou GQ, Qiu JM and Cheng CE: MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp. Am J Cancer Res. 8:2518–2527. 2018.PubMed/NCBI
18	Wang W, He Y, Rui J and Xu MQ: miR-410 acts as an oncogene in colorectal cancer cells by targeting dickkopf-related protein 1 via the Wnt/β-catenin signaling pathway. Oncol Lett. 17:807–814. 2019.PubMed/NCBI View Article : Google Scholar
19	Muhammad S, Tang Q, Wei L, Zhang Q, Wang G, Muhammad BU, Kaur K, Kamchedalova T, Gang Z, Jiang Z, et al: miRNA-30d serves a critical function in colorectal cancer initiation, progression and invasion via directly targeting the GNA13 gene. Exp Ther Med. 17:260–272. 2019.PubMed/NCBI View Article : Google Scholar
20	Xu C, Li S, Chen T, Hu H, Ding C, Xu Z, Chen J, Liu Z, Lei Z, Zhang HT, et al: miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncol Rep. 35:497–503. 2016.PubMed/NCBI View Article : Google Scholar
21	Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH, Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, et al: MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim Biophys Acta. 1843:2055–2066. 2014.PubMed/NCBI View Article : Google Scholar
22	Benson AB III, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, et al: NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 16:359–369. 2018.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43 (D1):D146–D152. 2015.PubMed/NCBI View Article : Google Scholar
25	Deng Z, Yan F, Jin Q, Wu J, Liu X and Zheng H: Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound. J Control Release. 174:109–116. 2014.PubMed/NCBI View Article : Google Scholar
26	Shi DM, Li LX, Bian XY, Shi XJ, Lu LL, Zhou HX, Pan TJ, Zhou J, Fan J and Wu WZ: miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. J Exp Clin Cancer Res. 37(294)2018.PubMed/NCBI View Article : Google Scholar
27	Maia D, de Carvalho AC, Horst MA, Carvalho AL, Scapulatempo-Neto C and Vettore AL: Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma. J Transl Med. 13(262)2015.PubMed/NCBI View Article : Google Scholar
28	Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1. Oncogene. 33:783–793. 2014.PubMed/NCBI View Article : Google Scholar
29	Lee H, Shin CH, Kim HR, Choi KH and Kim HH: MicroRNA-296-5p promotes invasiveness through downregulation of nerve growth factor receptor and Caspase-8. Mol Cells. 40:254–261. 2017.PubMed/NCBI View Article : Google Scholar
30	Conte A, Paladino S, Bianco G, Fasano D, Gerlini R, Tornincasa M, Renna M, Fusco A, Tramontano D and Pierantoni GM: High mobility group A1 protein modulates autophagy in cancer cells. Cell Death Differ. 24:1948–1962. 2017.PubMed/NCBI View Article : Google Scholar
31	Liu L, Zhang S, Hu L, Liu L, Guo W and Zhang J: HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3β signaling pathway. Mol Med Rep. 16:9287–9294. 2017.PubMed/NCBI View Article : Google Scholar
32	Colamaio M, Tosti N, Puca F, Mari A, Gattordo R, Kuzay Y, Federico A, Pepe A, Sarnataro D, Ragozzino E, et al: HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells. Expert Opin Ther Targets. 20:1169–1179. 2016.PubMed/NCBI View Article : Google Scholar
33	Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, et al: Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells. Exp Mol Med. 48(e255)2016.PubMed/NCBI View Article : Google Scholar
34	Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, et al: High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol Carcinog. 56:2146–2157. 2017.PubMed/NCBI View Article : Google Scholar
35	Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, et al: HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene. 37:5926–5938. 2018.PubMed/NCBI View Article : Google Scholar
36	Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y, Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett. 587:2467–2473. 2013.PubMed/NCBI View Article : Google Scholar
37	Zhang X, Tao T, Liu C, Guan H, Huang Y, Xu B and Chen M: Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1. Oncol Rep. 36:376–382. 2016.PubMed/NCBI View Article : Google Scholar
38	Zhou WB, Zhong CN, Luo XP, Zhang YY, Zhang GY, Zhou DX and Liu LP: miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. Biochem Biophys Res Commun. 470:838–844. 2016.PubMed/NCBI View Article : Google Scholar
39	Jia XP, Meng LL, Fang JC, Wang HW, Chen J, Zhou J, Wang CN and Jiang WF: Aberrant expression of miR-142-3p and its target gene HMGA1 and FZD7 in breast cancer and its clinical significance. Clin Lab. 64:915–921. 2018.PubMed/NCBI View Article : Google Scholar
40	Liu J, Mi B, Wang Y, Shi C, Mi X, Lu Y and Yu P: miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1. Oncol Lett. 15:8303–8310. 2018.PubMed/NCBI View Article : Google Scholar
41	Chandrasekaran KS, Sathyanarayanan A and Karunagaran D: MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells. Br J Cancer. 115:741–751. 2016.PubMed/NCBI View Article : Google Scholar
42	Lopez-Bertoni H, Lal B, Michelson N, Guerrero-Cázares H, Quiñones-Hinojosa A, Li Y and Laterra J: Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Oncogene. 35:4903–4913. 2016.PubMed/NCBI View Article : Google Scholar
43	Chaudhary S, Islam Z, Mishra V, Rawat S, Ashraf GM and Kolatkar PR: Sox2: A Regulatory Factor in Tumorigenesis and Metastasis. Curr Protein Pept Sci. 20:495–504. 2019.PubMed/NCBI View Article : Google Scholar
44	Xi Y, Li YS and Tang HB: High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells. Mol Cell Biochem. 374:173–180. 2013.PubMed/NCBI View Article : Google Scholar
45	Belton A, Xian L, Huso T, Koo M, Luo LZ, Turkson J, Page BD, Gunning PT, Liu G, Huso DL, et al: STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway. Leuk Lymphoma. 57:2681–2684. 2016.PubMed/NCBI View Article : Google Scholar
46	Capo A, Sepe R, Pellino G, Milone M, Malapelle U, Pellecchia S, Pepe F, Cacciola NA, Manigrasso M, Bruzzaniti S, et al: Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine (Lond). 15:231–242. 2019.PubMed/NCBI View Article : Google Scholar